TRASTUZUMAB DERUXTECAN + Palacaparib for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jun 2022: Trial registered, NCT05417594
  2. 24 Jun 2022: Trial started, NCT05417594

The trials

NCT05417594: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
695 planned
Started
24 Jun 2022
Primary completion
7 Feb 2028
Arms
Module 4 Part A: Dose escalation (AZD9574 + T-DXd), Module 4 Part B : Dose expansion (AZD9574 + T-DXd)
Results
None posted
  1. 14 Jun 2022: Trial registered
  2. 24 Jun 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.